Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 226-789-3 | CAS number: 5468-75-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 26 JUL 2000 to 02 OCT 2000
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Guideline study (OECD TG 422)
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 001
- Report date:
- 2001
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2,2'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-oxo-N-phenylbutyramide]
- EC Number:
- 228-787-8
- EC Name:
- 2,2'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-oxo-N-phenylbutyramide]
- Cas Number:
- 6358-85-6
- Molecular formula:
- C32H26Cl2N6O4
- IUPAC Name:
- 2,2'-[(3,3'-dichlorobiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(3-oxo-N-phenylbutanamide)
- Test material form:
- solid: nanoform
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- strain: Wistar Crl:(WI) BR (outbred, SPF)
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: approximately 14 weeks
- Weight at study initiation: group means males: 489-501 g; group means females: 267-271 g
- Fasting period before study: no
- Housing:
acclimatisation period: 5 animals per sex per cage, stainless steel suspended cages with wire mesh floors
mating period: 1 female together with 1 male, stainless steel suspended cages with wire mesh floors
after mating: animals were housed individually, Macrolon cages (Type III)
- Diet: standard pelleted laboratory animal diet (Carfil Quality BVBA, Oud-Turnhout, Belgium), ad libitum
- Water: tap water, ad libitum
- Acclimation period: 26 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 +/- 3
- Humidity (%): 30-70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: polyethylene glycol 400
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
- formulations (w/w) were prepared daily within 4 hours prior to dosing
- storage at ambient temperature
VEHICLE
- vehicle: polyethylene glycol 400, specific gravity: 1.125
- Justification for use and choice of vehicle: based on trial fromulations
- Concentration in vehicle: 0 mg/g; 4.45 mg/g; 17.8 mg/g; 89.9 mg/g
- Amount of vehicle: 10 ml/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analytical study was performed to check accuracy of preparation and to determine stability and homogeneity of test substance preparation.
Test samples were dissolved in chloroform by sonication and analysed spectrophotometrically. - Details on mating procedure:
- - M/F ratio per cage: 1/1
- Length of cohabitation: up to 14 days
- Proof of pregnancy: copulation plugs in the cage, sperm in vaginal smear referred to as day 0 of pregnancy
- After 14 days of unsuccessful pairing replacement of first male by another male with proven fertility.
- Further matings after two unsuccessful attempts: no
- After successful mating each pregnant female was caged: individually
- Any other deviations from standard protocol: no - Duration of treatment / exposure:
- F0-males:
- for 2 weeks prior to mating, throughout mating and after mating at least until the minimum total dosing period of 28 days had been completed
F0-females:
2 weeks prior to mating, throughout mating, and pregnancy and at least up to, and including the day before sacrifice - Frequency of treatment:
- once daily
- Duration of test:
- Start treatment: 2000-08-21
Start terminal procedures: F0-males: 2000-09-19; F0-females: 2000-10-02
Doses / concentrationsopen allclose all
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on the results of a dose range finding study with the test item (5 days oral exposure of male and female rats to 50, 200 and 1000 mg/kg bw/day did not cause changes in clinical appearance, body weights, food consumption, macroscopic examination and organ weights)
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily in the home cage and twice during the complete study in a standard arena
BODY WEIGHT: Yes
- Time schedule for examinations:
F0-females: on the first day of dosing and weekly thereafter
mated femaes were weighed daily from day 0 until day 20 of gestation inclusive
F0-females were weighed daily during lactation
FOOD CONSUMPTION: Yes
- Time schedule for examinations: weekly, but not during the mating period
WATER CONSUMPTION: Yes
- Time schedule for examinations: subjective appraisal during the study, no quantitative investigation
OTHER:
Observations on haematology, clinical chemistry and neurobehavioural examination are reported in section 7.5.1
- Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: No data
- Number of late resorptions: No data - Fetal examinations:
- - The number and sex (by assessment of the ano-congenital distance) of pups, of stillbirths,
of live births, and of runts within 24 hours of parturition (day 0 or 1 post partum)
- The number en sex of live pups an day 4 post partum
- The weight of all litters within 24 hours of parturition and an day 4 post partum
- The number of pups with physical or behavioural abnormalities (daily)
- The number of pups with externally visible macroscopic abnormalities (daily) - Statistics:
- - Dunnett-test
- Steel-test
- exact Fisher-test
- Indices:
- Reproductive indices:
- percentage mating: (number of females mated)/(number of females paired) * 100
- fertility index: (number of animals pregnant or siring a litter)/(number of females paired) * 100
- conception index: (number of animals pregnant)/(number of females mated) *100
- gestation index: (number bearing live pups)/(number pregnant) * 100
Offspring viability indices:
- percentage live males at first litter check: (number of live male pups)/(number of live pups) * 100
- percentage live females at first litter check: (number of live female pups)/(number of live pups) * 100
- viability index: (number of live pups on day 4 P.P.)/(number of live pups born alive) * 100
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:no effects
Details on maternal toxic effects:
CLINICAL SIGNS AND MORTALITY (PARENTAL ANIMALS)
No treatment related clinical signs were observed (see section 7.5.1).
BODY WEIGHT AND FOOD CONSUMPTION (PARENTAL ANIMALS)
Body weights and body weight gain of treated animals remained in the same range as controls (see section 7.5.1).
TEST SUBSTANCE INTAKE (PARENTAL ANIMALS)
There were no differences in food consumption (absolute and relative) between treated and control animals (see section 7.5.1).
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS)
Four females (one female in each group) were non-pregnant.
The average number of implantation sites in pregnant females receiving 50, 200 or 1000 mg/kg/day was 13.7, 16.3 and 15.2, respectively, compared with a mean figure of 14.7 for the control group. These values are within the range expected in control rats of this age and strain, and give no indication of a treatment-related disturbance.
The majority of pairs mated during the first 4 days of the mating period. Mean pre-coital times were similar for treated and control groups.
For each dose group, 100% mating was confirmed. The fertility and conception indices were similar for treated and control groups. The gestation Index was 100% for all treatment groups.
ORGAN WEIGHTS (PARENTAL ANIMALS)
Organ weights and organ:body weight ratlos of treated animals were considered to be similar to those of control animals.
GROSS PATHOLOGY (PARENTAL ANIMALS)
Macroscopic observations of the remaining animals at necropsy did not reveal any alterations that were considered to have arisen as a result of treatment.
HISTOPATHOLOGY (PARENTAL ANIMALS)
There were no microscopic findings recorded which could be attributed to treatment with the test substance.
OTHER FINDINGS:
BREEDING DATA:
The mean duration of gestation of treated females was similar to that of the control females and ranged between 21.4 and 22.0 days.
Effect levels (maternal animals)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Basis for effect level:
- other: maternal toxicity
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Basis for effect level:
- other: developmental toxicity
Maternal abnormalities
- Key result
- Abnormalities:
- no effects observed
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
VIABILITY (OFFSPRING)
The number of living and dead pups at first litter check revealed similar values for treated and control groups. Postnatal loss between days 0-4 post partum showed a statistical significant increase in the 50 mg/kg dose group. Consequently, the viability Index of this group was statistical significant decreased. This was considered to be caused mainly by the loss of one litter, therefore no toxicological significance was attached to this finding.
CLINICAL SIGNS (OFFSPRING)
No unexpected clinical signs were recorded among pups of any dose group. The incidences of the small number of findings were within expected limits and showed no relationship to dose. They included no milk in stomach, hypothermia, smell appearance, open skull and back, curled tail, prothrusion of the tongue, autolytic pup, yellow skin, haemorrhage on stomach, and broken tail.
BODY WEIGHT (OFFSPRING)
No statistically significant group differences were recorded for body weights of pups at days 1 and 4 post partum.
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no changes in examined parameters observed
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- There were no changes in clinical appearance, functional observations, body weights, food consumption, clinical laboratory investigations, reproduction, litter observation, macroscopic examination, organ weights and microscopic examination that were considered to be an effect of treatment.
From the results presented in this report a definitive No Observed Adverse Effect Level (NOAEL) for parental and reproduction/developmental toxicity for the test item of 1000 mg/kg/day was established. - Executive summary:
A combined repeated dose toxicity study with reproduction/developmental toxicity screening test with the test item administered by oral gavage in Wistar rats (10/sex/dose) was performed according to OECD TG 422. The dose levels for this study were 0, 50, 200 and 1000 mg/kg bw/day. Oral dosing of male and fernale Wistar rats with the test item at dose levels of 50, 200 or 1000 mg/kg b.w./day for at least 28 days, revealed no treatment-related findings on parental animals, on fertility, on embryo-foetal development, or on pup development. From the results presented in this report a definitive No Observed Adverse Effect Level (NOAEL) for parental and reproduction/developmental toxicity for the test item of 1000 mg/kg/day was established.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)